In short
This article discusses clinical trials investigating the use of a drug containing allergen extract from Poa Pratensis (Kentucky bluegrass) pollen, modified with glutaraldehyde, for treating allergies. The trials aim to assess the effectiveness and safety of this immunotherapy approach for patients with allergic rhinitis, rhinoconjunctivitis, and mild asthma caused by grass and tree pollen allergies.
At a glance
- Study Type
- Phase III clinical trials
- Drug Composition
- Allergen extracts from grass pollens (including Poa Pratensis) and tree pollens, modified with glutaraldehyde
- Administration Method
- Subcutaneous injection
- Target Conditions
- Moderate to severe allergic rhinitis/rhinoconjunctivitis, with or without mild-moderate controlled asthma
- Primary Outcome
- Overall symptom and medication scores during relevant pollen seasons
- Key Secondary Outcomes
- Symptom-free days, medication-free days, asthma exacerbations, quality of life, immunological parameters
- Participant Age Range
- 12-65 years
- Treatment Duration
- Up to 12 months
- Safety Assessments
- Monitoring of adverse events, including local and systemic reactions
What is Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified?
Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified is a specialized medication used in the treatment of grass pollen allergies. It is part of a group of treatments known as allergen extracts. This particular extract is derived from the pollen of Poa pratensis, commonly known as Kentucky bluegrass. The extract is modified using glutaraldehyde, a chemical that alters the structure of the allergens to make them more effective for treatment.
How Does It Work?
This medication works through a process called immunotherapy. By exposing your body to small, controlled amounts of the allergen (in this case, modified grass pollen), your immune system gradually becomes less sensitive to it. Over time, this can reduce your allergic reactions when you're exposed to grass pollen in your environment.
What Conditions Does It Treat?
Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified is primarily used to treat: Allergic rhinitis (hay fever) caused by grass pollen Allergic rhinoconjunctivitis (affecting both nose and eyes) due to grass pollen Mild to moderate allergic asthma associated with grass pollen allergy These conditions can range from intermittent (occurring occasionally) to persistent (ongoing).
How Is It Administered?
This medication is administered as a subcutaneous injection, which means it's injected just under the skin. The treatment is typically given by a healthcare professional in a clinical setting. The maximum daily dose is 0.5 ml, and the treatment can last up to 12 months.
Current Clinical Trials
As of now, there are ongoing clinical trials to further evaluate the effectiveness and safety of this treatment. These trials are combining the Poa pratensis extract with other grass and tree pollen extracts to create more comprehensive allergy treatments.
Efficacy and Safety
The ongoing clinical trials aim to assess both the efficacy and safety of these allergen extracts. They're looking at various factors, including: Overall symptom and medication scores during pollen seasons Number of symptom-free and medication-free days Frequency of asthma exacerbations Changes in quality of life Changes in immunological parameters (like specific IgE and IgG4 levels) These trials are designed to provide comprehensive data on how well the treatment works and its safety profile.
Potential Side Effects
As with any medical treatment, there may be side effects. The clinical trials are closely monitoring for any adverse events, including: Reactions at the injection site Systemic allergic reactions Any other unexpected side effects It's important to note that the medication is being tested in a controlled clinical setting to ensure patient safety.
Who Is Eligible for This Treatment?
While the specific criteria may vary, generally, this treatment may be suitable for: Individuals aged 12-65 years Those with confirmed grass pollen allergies Patients with moderate to severe allergic rhinitis or rhinoconjunctivitis Some patients with mild to moderate allergic asthma However, there are also several conditions that might make someone ineligible for this treatment, such as severe asthma, certain autoimmune diseases, or pregnancy. Always consult with a healthcare professional to determine if this treatment is appropriate for you.